Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Upamostat - Link Health Group/RedHill Biopharma

Next Previous
Drug Profile

Upamostat - Link Health Group/RedHill Biopharma

Alternative Names: Mesupron; RHB-107; WX-671

Latest Information Update: 09 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wilex
  • Developer Heidelberg Pharma AG; Link Health Group; RedHill Biopharma; WILEX AG
  • Class Amines; Antineoplastics; Antivirals; Imides; Piperazines; Small molecules; Sulfonamides
  • Mechanism of Action Serine endopeptidase inhibitors; Urokinase-type plasminogen activator inhibitors; Virus internalisation inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III COVID 2019 infections
  • Phase II Breast cancer; Pancreatic cancer
  • Preclinical Cholangiocarcinoma; Ebola virus infections; Influenza virus infections
  • No development reported Cancer; Gastrointestinal disorders; Solid tumours
  • Discontinued Head and neck cancer

Most Recent Events

  • 28 Apr 2025 RedHill Biopharma has patents pending for Upamostat in China
  • 28 Apr 2025 Efficacy data from a phase II clinical trial in COVID-2019 infections released by RedHill Biopharma
  • 28 Feb 2025 No recent reports of development identified for clinical-Phase-Unknown development in Gastrointestinal-disorders in Unknown (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top